QIAGEN and Bio*One Capital Enter into Joint Venture to Develop Molecular Diagnostics Products

Assay development centre for Singapore will support QIAGEN in the market for molecular testing solutions

05-Dec-2007

QIAGEN and Bio*One Capital announced that they have entered into a joint venture to establish Dx Assays Pte Ltd ("Dx Assays"). Dx Assays expects to be one of the first centres in Singapore for assay development in which molecular diagnostics for infectious and genetic diseases will be developed. The centre is expected to be fully operational by early 2008, employ more than 30 scientists and be equipped with state-of-the-art technology.

"The in-depth expertise and talent pool in biomedical research makes Singapore an ideal location for a centre for assay development", said Peer Schatz, CEO of QIAGEN. "This joint venture brings to QIAGEN further resources to contribute to our goal to further broaden our global portfolio of molecular testing solutions, to further accelerate our development speed and to expand our market and technology leadership in this fastest growing segment of diagnostics. Together with Bio*One, we will support this new venture's expansion into what we expect to be one of the world's premier suppliers of molecular diagnostic assay development solutions to major pharmaceutical and biotech companies. We look forward to this significant increase of our assay development capacities and capabilities which currently includes assay development teams in Hamburg, Gaithersburg / Maryland and Shenzhen."

The new Singapore venture is QIAGEN's latest step in the expansion of its presence in the rapidly growing Asian markets. With growth rates of up to 60%, Asia today is the Company's fastest growing sector, with Singapore taking significant market share. QIAGEN's strategic expansion into the region began in 2005. Today QIAGEN maintains 12 Asian offices with approximately 300 employees, including more than 50 in Singapore. Including the subsidiary in Japan, they contribute approximately 10 per cent to QIAGEN's overall net sales.

https://www.bionity.com/en/news/75407/qiagen-and-bio-one-capital-enter-into-joint-venture-to-develop-molecular-diagnostics-products.html